The oral presentations will highlight safety and efficacy data for a completed phase 2 study of the company’s lead clinical asset, NiCord, as a single cord blood graft, and proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer.
Phase 2 NiCord Data in Allogeneic Bone Marrow Transplant and Preclinical Data for NK Cells to be Presented in Oral Presentations
JERUSELUM--(BUSINESS WIRE)-- Gamida Cell, a leading cellular and immune therapeutics company, today announced that two oral presentations on new data from the company’s pipeline programs will be presented during the 59th Annual Meeting of the American Society for Hematology (ASH).
The oral presentations will highlight safety and efficacy data for a completed phase 2 study of the company’s lead clinical asset, NiCord, as a single cord blood graft, and proof-of-concept data for the advancement of natural killer cells (NK cells) as an immunotherapeutic modality for patients with cancer. These abstracts are now available on the ASH conference website.
Oral Presentations
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial
Date & Time: Monday, December 11, 2017 at 4:30 p.m. ET
Session Name: Clinical Allogeneic Transplantation: Results: Donor Selection in the Haplo Transplant Era
Abstract Number: 847
Location: Georgia World Congress Center, Building C, Level 2, Room C202-204
Enhanced In Vivo Persistence and Proliferation of NK Cells Expanded in Culture with the Small Molecule Nicotinamide: Development of a Clinical-Applicable Method for NK Expansion
Date & Time: Monday, December 11, 2017 at 11:00 a.m. ET
Session Name: Cell Collection and Processing: Optimization of Hematopoietic Graft Using Small Molecules in Culture
Abstract Number: 657
Location: Georgia World Congress Center, Building B, Level 2, Room B216-217
About Gamida Cell
Gamida Cell is a leader in cellular and immune therapeutics dedicated to treating patients with cancer and rare genetic diseases. The company is building a diverse pipeline based on its proprietary NAM Technology platform to deliver transformative medicines to patients in need of new treatment options. To learn more about Gamida Cell, including current clinical studies, please visit www.gamida-cell.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171101005596/en/
Contacts
Pure Communications
Katie Engleman, +1-910-509-3977
katie@purecommunications.com
or
Investor Contact:
Stern Investor Relations, Inc.
Christina Tartaglia, +1-212-362-1200
christinabeth@sternir.com
Source: Gamida Cell
View this news release online at:
http://www.businesswire.com/news/home/20171101005596/en
